Bolt Biotherapeutics Q3 2026 Results: Net Loss of $4.42M, Loss Narrows
Bolt Biotherapeutics reported a net loss of $19.5 million for the nine months ended September 30, 2026, a significant reduction from the $26.7 million loss in the prior year period. The company recently acquired Prana Therapies, Inc. to pivot its focus toward the INSPIRE platform for multispecific antibodies while completing Phase 1/2 trials for BDC-4182.
- Key figure
- Net loss $4.42M